Literature DB >> 33398403

Mitochondrial bioenergetic deficits in C9orf72 amyotrophic lateral sclerosis motor neurons cause dysfunctional axonal homeostasis.

Arpan R Mehta1,2,3,4,5, Jenna M Gregory1,2,4,6,7, Owen Dando1,8, Roderick N Carter9, Karen Burr1,2,4, Jyoti Nanda1,2,4, David Story1,2,4, Karina McDade6, Colin Smith2,4,6,7, Nicholas M Morton9, Don J Mahad2,3, Giles E Hardingham1,4,8, Siddharthan Chandran10,11,12,13,14, Bhuvaneish T Selvaraj15,16,17,18.   

Abstract

Axonal dysfunction is a common phenotype in neurodegenerative disorders, including in amyotrophic lateral sclerosis (ALS), where the key pathological cell-type, the motor neuron (MN), has an axon extending up to a metre long. The maintenance of axonal function is a highly energy-demanding process, raising the question of whether MN cellular energetics is perturbed in ALS, and whether its recovery promotes axonal rescue. To address this, we undertook cellular and molecular interrogation of multiple patient-derived induced pluripotent stem cell lines and patient autopsy samples harbouring the most common ALS causing mutation, C9orf72. Using paired mutant and isogenic expansion-corrected controls, we show that C9orf72 MNs have shorter axons, impaired fast axonal transport of mitochondrial cargo, and altered mitochondrial bioenergetic function. RNAseq revealed reduced gene expression of mitochondrially encoded electron transport chain transcripts, with neuropathological analysis of C9orf72-ALS post-mortem tissue importantly confirming selective dysregulation of the mitochondrially encoded transcripts in ventral horn spinal MNs, but not in corresponding dorsal horn sensory neurons, with findings reflected at the protein level. Mitochondrial DNA copy number was unaltered, both in vitro and in human post-mortem tissue. Genetic manipulation of mitochondrial biogenesis in C9orf72 MNs corrected the bioenergetic deficit and also rescued the axonal length and transport phenotypes. Collectively, our data show that loss of mitochondrial function is a key mediator of axonal dysfunction in C9orf72-ALS, and that boosting MN bioenergetics is sufficient to restore axonal homeostasis, opening new potential therapeutic strategies for ALS that target mitochondrial function.

Entities:  

Keywords:  Amyotrophic lateral sclerosis; Axon; Energy metabolism; Frontotemporal dementia; Mitochondria; Motor neuron; Neurodegeneration

Year:  2021        PMID: 33398403     DOI: 10.1007/s00401-020-02252-5

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  102 in total

1.  Characterizing gene sets with FuncAssociate.

Authors:  Gabriel F Berriz; Oliver D King; Barbara Bryant; Chris Sander; Frederick P Roth
Journal:  Bioinformatics       Date:  2003-12-12       Impact factor: 6.937

Review 2.  PGC1α and mitochondrial metabolism--emerging concepts and relevance in ageing and neurodegenerative disorders.

Authors:  Shane Austin; Julie St-Pierre
Journal:  J Cell Sci       Date:  2012-11-01       Impact factor: 5.285

3.  Discriminative stimulus properties of chlordiazepoxide and zolpidem. Agonist and antagonist effects of CGS 9896 and ZK 91296.

Authors:  D J Sanger; B Zivkovic
Journal:  Neuropharmacology       Date:  1987-05       Impact factor: 5.250

4.  Impact of PGC-1α on the topology and rate of superoxide production by the mitochondrial electron transport chain.

Authors:  Shane Austin; Eva Klimcakova; Julie St-Pierre
Journal:  Free Radic Biol Med       Date:  2011-09-10       Impact factor: 7.376

5.  TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis.

Authors:  Tetsuaki Arai; Masato Hasegawa; Haruhiko Akiyama; Kenji Ikeda; Takashi Nonaka; Hiroshi Mori; David Mann; Kuniaki Tsuchiya; Mari Yoshida; Yoshio Hashizume; Tatsuro Oda
Journal:  Biochem Biophys Res Commun       Date:  2006-10-30       Impact factor: 3.575

6.  C9orf72 expansion within astrocytes reduces metabolic flexibility in amyotrophic lateral sclerosis.

Authors:  Scott P Allen; Benjamin Hall; Ryan Woof; Laura Francis; Noemi Gatto; Allan C Shaw; Monika Myszczynska; Jordan Hemingway; Ian Coldicott; Amelia Willcock; Lucy Job; Rachel M Hughes; Camilla Boschian; Nadhim Bayatti; Paul R Heath; Oliver Bandmann; Heather Mortiboys; Laura Ferraiuolo; Pamela J Shaw
Journal:  Brain       Date:  2019-12-01       Impact factor: 13.501

Review 7.  C9orf72-mediated ALS and FTD: multiple pathways to disease.

Authors:  Rubika Balendra; Adrian M Isaacs
Journal:  Nat Rev Neurol       Date:  2018-09       Impact factor: 42.937

8.  Axonal transport of TDP-43 mRNA granules is impaired by ALS-causing mutations.

Authors:  Nael H Alami; Rebecca B Smith; Monica A Carrasco; Luis A Williams; Christina S Winborn; Steve S W Han; Evangelos Kiskinis; Brett Winborn; Brian D Freibaum; Anderson Kanagaraj; Alison J Clare; Nisha M Badders; Bilada Bilican; Edward Chaum; Siddharthan Chandran; Christopher E Shaw; Kevin C Eggan; Tom Maniatis; J Paul Taylor
Journal:  Neuron       Date:  2014-02-05       Impact factor: 17.173

9.  Axonal transport defects are a common phenotype in Drosophila models of ALS.

Authors:  Katie R Baldwin; Vinay K Godena; Victoria L Hewitt; Alexander J Whitworth
Journal:  Hum Mol Genet       Date:  2016-04-07       Impact factor: 6.150

10.  ALS--dying forward, backward or outward?

Authors:  Mark R Baker
Journal:  Nat Rev Neurol       Date:  2014-09-23       Impact factor: 42.937

View more
  27 in total

Review 1.  Genetics of amyotrophic lateral sclerosis: seeking therapeutic targets in the era of gene therapy.

Authors:  Naoki Suzuki; Ayumi Nishiyama; Hitoshi Warita; Masashi Aoki
Journal:  J Hum Genet       Date:  2022-06-13       Impact factor: 3.172

Review 2.  Human stem cell models of neurodegeneration: From basic science of amyotrophic lateral sclerosis to clinical translation.

Authors:  Elisa Giacomelli; Björn F Vahsen; Elizabeth L Calder; Yinyan Xu; Jakub Scaber; Elizabeth Gray; Ruxandra Dafinca; Kevin Talbot; Lorenz Studer
Journal:  Cell Stem Cell       Date:  2022-01-06       Impact factor: 24.633

3.  Association between mitochondrial and nuclear DNA damages and cellular senescence in the patients with biliary atresia undergoing Kasai portoenterostomy and liver transplantation.

Authors:  Yudai Nakajima; Yuto Yamazaki; Xin Gao; Masatoshi Hashimoto; Masaki Nio; Motoshi Wada; Fumiyoshi Fujishima; Hironobu Sasano
Journal:  Med Mol Morphol       Date:  2022-03-03       Impact factor: 2.309

4.  Assessment of Mitochondrial Trafficking as a Surrogate for Fast Axonal Transport in Human Induced Pluripotent Stem Cell-Derived Spinal Motor Neurons.

Authors:  Arpan R Mehta; Siddharthan Chandran; Bhuvaneish T Selvaraj
Journal:  Methods Mol Biol       Date:  2022

5.  Single-cell transcriptomics identifies master regulators of neurodegeneration in SOD1 ALS iPSC-derived motor neurons.

Authors:  Seema C Namboori; Patricia Thomas; Ryan Ames; Sophie Hawkins; Lawrence O Garrett; Craig R G Willis; Alessandro Rosa; Lawrence W Stanton; Akshay Bhinge
Journal:  Stem Cell Reports       Date:  2021-11-11       Impact factor: 7.765

Review 6.  Axon Biology in ALS: Mechanisms of Axon Degeneration and Prospects for Therapy.

Authors:  Michael P Coleman
Journal:  Neurotherapeutics       Date:  2022-10-07       Impact factor: 6.088

7.  Motor Neuron Disease Systematic Multi-Arm Adaptive Randomised Trial (MND-SMART): a multi-arm, multi-stage, adaptive, platform, phase III randomised, double-blind, placebo-controlled trial of repurposed drugs in motor neuron disease.

Authors:  Charis Wong; Rachel S Dakin; Jill Williamson; Judith Newton; Michelle Steven; Shuna Colville; Maria Stavrou; Jenna M Gregory; Elizabeth Elliott; Arpan R Mehta; Jeremy Chataway; Robert J Swingler; Richard Anthony Parker; Christopher J Weir; Nigel Stallard; Mahesh K B Parmar; Malcolm R Macleod; Suvankar Pal; Siddharthan Chandran
Journal:  BMJ Open       Date:  2022-07-07       Impact factor: 3.006

Review 8.  The Link between Oxidative Stress, Redox Status, Bioenergetics and Mitochondria in the Pathophysiology of ALS.

Authors:  Elena Obrador; Rosario Salvador-Palmer; Rafael López-Blanch; Ali Jihad-Jebbar; Soraya L Vallés; José M Estrela
Journal:  Int J Mol Sci       Date:  2021-06-14       Impact factor: 5.923

9.  Synaptic disruption and CREB-regulated transcription are restored by K+ channel blockers in ALS.

Authors:  Alberto Catanese; Sandeep Rajkumar; Daniel Sommer; Dennis Freisem; Alexander Wirth; Amr Aly; David Massa-López; Andrea Olivieri; Federica Torelli; Valentin Ioannidis; Joanna Lipecka; Ida Chiara Guerrera; Daniel Zytnicki; Albert Ludolph; Edor Kabashi; Medhanie A Mulaw; Francesco Roselli; Tobias M Böckers
Journal:  EMBO Mol Med       Date:  2021-06-14       Impact factor: 12.137

10.  Synaptopathy Mechanisms in ALS Caused by C9orf72 Repeat Expansion.

Authors:  Agnes L Nishimura; Natalia Arias
Journal:  Front Cell Neurosci       Date:  2021-06-01       Impact factor: 5.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.